Preclinical Studies

Editorial: Sonja Sherritze, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherGreg Pessagno, National Account ManagerKim Kleinberg, National Account ManagerProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/orchard-therapeutics-present-37th-annual-jp-morgan-healthcare-conference-january-9-2019

by

Allschwil, Switzerland – December 18, 2018Idorsia Ltd (SIX: IDIA) today announced that Phase 2 clinical studies with selatogrel (recommended INN for ACT-246475), Idorsia’s P2Y12 receptor antagonist, in patients with stable coronary artery disease (CAD) and patients with acute myocardial infarction (AMI) have met their pharmacodynamic objectives of significantly inhibiting platelet aggregation. Subcutaneous administration of selatogrel […]

by

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to the investment industry. A search is underway to find a successor to […]

by

– New Study with Largest Data Set to Date Demonstrates that Adjunctive Use of WATS3D Significantly Increases Detection of Esophageal Precancer – – Study Published in Diseases of the Esophagus – SUFFERN, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) — CDx Diagnostics today announced the publication of new data demonstrating that the addition of WATS3D (Wide […]

by

VANCOUVER, British Columbia, Dec. 21, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the Company has entered into a share exchange agreement with three separate individuals for the issuance of 14,583,333, 14,583,333 and 12,500,000 common shares of Veritas at $0.12 […]

by

Editorial: Sonja Sherritze, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherGreg Pessagno, National Account ManagerKim Kleinberg, National Account ManagerProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/zogenix-reports-granting-inducement-awards-under-nasdaq-listing-rule-5635c4-6

by

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 24, 2018 (GLOBE NEWSWIRE) — Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”) is pleased to announce that it has received approval from Health Canada to sell Cannabis, effective December 21, 2018, in accordance with sections […]

by

– Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point –– AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration agreement –– AGTC on schedule to advance its Phase 1/2 clinical studies in […]

by

Findlay Park Partners Llp decreased American Express Co (AXP) stake by 11.64% reported in 2018Q3 SEC filing. Findlay Park Partners Llp sold 569,544 shares as American Express Co (AXP)’s stock declined 1.40%. The Findlay Park Partners Llp holds 4.32 million shares with $460.46M value, down from 4.89M last quarter. American Express Co now has $80.07 […]

by

IRVINE, Calif., Dec. 28, 2018 (GLOBE NEWSWIRE) — Gala Pharmaceutical California Inc., a subsidiary of Gala Pharmaceutical, Inc. (Ticker: GLPH), today announced it has received a Temporary License from the State of California for its flagship cannabis testing facility to be located in Long Beach, California.  The Company expects to begin construction on the state-of-the-art […]

by

SAINT PETERSBURG, FL, Dec. 10, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations, and cannabis delivery technologies for the healthcare and consumer care industry, is pleased to announce the Company’s plans to roll out of their new line of CBD products for […]

by

Providing Effective Skin Care Products This profile is part of a paid investor education campaign.* Overview Therma Bright Inc. (TSXV:THRM) (“Therma Bright”) is a progressive medical device technology company that is focused on serving the $21 billion cosmeceutical industry. The company holds and is seeking various trademarks and patents for its thermal therapy technology that uses […]

by

By Staff. The National Institutes of Health (NIH) has awarded $997,068 to a biopharmaceutical company to conduct preclinical research to evaluate the potential of NSI-189, which is a small molecule compound, for the prevention and treatment of diabetic neuropathy. Neuralstem, Inc. (Nasdaq:CUR) announced it was awarded a Phase 2 Small Business Innovation Research (SBIR) grant […]

by

Cim Llc increased Svb Finl Group (SIVB) stake by 98.05% reported in 2018Q3 SEC filing. Cim Llc acquired 1,862 shares as Svb Finl Group (SIVB)’s stock declined 37.00%. The Cim Llc holds 3,761 shares with $1.17 million value, up from 1,899 last quarter. Svb Finl Group now has $9.93 billion valuation. The stock decreased 1.71% […]

by